Hangzhou Tigermed Consulting Co., Ltd Share Price
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.84 CNY | -0.55% |
|
-2.12% | -11.15% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 38.91B 5.47B 418B | P/E ratio 2024 * |
24.7x | P/E ratio 2025 * | 20x |
|---|---|---|---|---|---|
| Enterprise value | 40.35B 5.67B 434B | EV / Sales 2024 * |
4.48x | EV / Sales 2025 * | 3.86x |
| Free-Float |
71.17% | Yield 2024 * |
0.79% | Yield 2025 * | 1.09% |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
| 1 day | -0.55% | ||
| 1 week | -2.12% | ||
| Current month | -3.99% | ||
| 1 month | -9.17% | ||
| 3 months | -12.63% | ||
| 6 months | +13.48% | ||
| Current year | -11.15% |
1 week
47.26
50.87
1 month
47.1954.23
Current year
36.1263.36
1 year
36.1273.19
3 years
36.12180.00
5 years
36.12209.41
10 years
9.68209.41
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 50 | 31/08/22 |
Hao Wu
PSD | President | 56 | 31/12/19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 31/12/04 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Zhi Min Chen
BRD | Director/Board Member | 64 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.55% | -2.12% | -22.01% | -67.72% | 5.5B | ||
| -0.44% | +1.72% | +11.95% | -28.77% | 46.38B | ||
| -0.75% | -4.92% | +8.84% | -7.68% | 43.26B | ||
| +1.36% | +5.88% | +25.80% | +43.32% | 33.62B | ||
| -17.05% | -9.71% | -36.99% | -84.20% | 30.56B | ||
| +2.57% | +2.84% | +31.01% | -22.43% | 29.37B | ||
| +1.90% | -3.83% | +15.13% | +15.36% | 24B | ||
| -0.72% | -1.89% | +53.45% | +63.82% | 15.4B | ||
| -1.90% | +0.22% | +0.78% | -42.27% | 11.66B | ||
| +1.64% | -1.42% | +22.51% | +84.49% | 10.35B | ||
| Average | -1.36% | +0.24% | +11.05% | -4.61% | 25.01B | |
| Weighted average by Cap. | -1.64% | +0.48% | +11.56% | -8.32% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 7.68B 1.08B 82.58B | 8.88B 1.25B 95.47B |
| Net income | 1.68B 237M 18.11B | 2.07B 291M 22.29B |
| Net Debt | -5.63B -791M -60.54B | -6.94B -975M -74.61B |
More financial data
* Estimated data
Employees
0
Calendar
29/10/2024
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/24 | 48.84 ¥ | -0.55% | 3,845,410 |
| 11/09/24 | 49.11 ¥ | +0.39% | 4,333,990 |
| 10/09/24 | 48.92 ¥ | -0.57% | 5,773,199 |
| 09/09/24 | 49.20 ¥ | +0.96% | 5,974,986 |
| 06/09/24 | 48.73 ¥ | -3.43% | 4,032,195 |
End-of-day quote Shenzhen S.E., September 11, 2024
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
48.84CNY
Average target price
69.82CNY
Spread / Average Target
+42.96%
- Stock Market
- Equities
- 300347 Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition